Con: Nutritional vitaminDreplacement in chronic kidney disease and end-stage renal disease

dc.contributor.authorAgarwal, Rajiv
dc.contributor.authorGeorgianos, Panagiotis I.
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2016-12-09T15:54:12Z
dc.date.available2016-12-09T15:54:12Z
dc.date.issued2016
dc.description.abstractInsufficiency of 25-hydroxyvitamin D [25(OH)D] is highly prevalent among patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD) and is a critical component in the pathogenesis of secondary hyperparathyroidism. Accordingly, current National Kidney Foundation—Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes guidelines recommend the correction of hypovitaminosis D through nutritional vitamin D replacement as a first-step therapeutic approach targeting secondary hyperparathyroidism. In this Polar Views debate, we summarize the existing evidence, aiming to defend the position that nutritional vitamin D replacement is not evidence-based and should not be applied to patients with CKD. This position is supported by the following: (i) our meta-analysis of randomized controlled trials shows that whereas nutritional vitamin D significantly increases serum 25(OH)D levels relative to placebo, there is no evidence either in predialysis CKD or in ESRD that parathyroid hormone (PTH) is lowered; (ii) on the other hand, in randomized head-to-head comparisons, nutritional vitamin D is shown to be inferior to activated vitamin D analogs in reducing PTH levels; (iii) nutritional vitamin D is reported to exert minimal to no beneficial actions in a series of surrogate risk factors, including aortic stiffness, left ventricular mass index (LVMI), epoetin utilization and immune function among others; and (iv) there is no evidence to support a benefit of nutritional vitamin D on survival and other ‘hard’ clinical outcomes. Whereas nutritional vitamin D replacement may restore 25(OH)D concentration to near normal, the real target of treating vitamin D insufficiency is to treat secondary hyperparathyroidism, which is untouched by nutritional vitamin D. Furthermore, the pleotropic benefits of nutritional vitamin D remain to be proven. Thus, there is little, if any, benefit of nutritional vitamin D replacement in CKD.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationAgarwal, R., & Georgianos, P. I. (2016). Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrology Dialysis Transplantation, 31(5), 706-713.en_US
dc.identifier.urihttps://hdl.handle.net/1805/11591
dc.language.isoenen_US
dc.publisherOxforden_US
dc.relation.isversionof10.1093/ndt/gfw080en_US
dc.relation.journalNephrology Dialysis Transplantationen_US
dc.rightsCC0 1.0 Universal
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.sourcePublisheren_US
dc.subjectcholecalciferolen_US
dc.subjectCKDen_US
dc.subjectnutritional vitamin Den_US
dc.titleCon: Nutritional vitaminDreplacement in chronic kidney disease and end-stage renal diseaseen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Agarwal_2016_con.pdf
Size:
468.15 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: